BRISTOL MYERS SQUIBB

iTeos Therapeutics' mid-stage trial results show its drug, when combined with GSK's immunotherapy, shrank lung tumors in twice as many patients compared to GSK's therapy alone. The trial raised safety concerns due to three treatment-related deaths from immune-related inflammation. Despite previous failures of TIGIT-targeting drugs, iTeos' data could rekindle interest in the target, with further data expected to clarify the combination's impact on survival and disease progression.

BMS's BMS-986012 nearly doubled overall survival in ES-SCLC patients with brain metastases in a Phase II trial, with an OS of 16.3 months vs. 8.7 months in the control group. The study compares BMS-986012, Opdivo, and chemotherapy versus Opdivo plus chemotherapy.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

Immunocore Holdings plc (NASDAQ: IMCR) develops TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases using its ImmTAC platform. Notable products include KIMMTRAK for metastatic uveal melanoma. Recent collaborations include a Phase 3 trial with Bristol Myers Squibb for advanced cutaneous melanoma. The company's pipeline includes programs for HBV and solid tumors, with a mission to improve patient outcomes.

Bristol Myers Squibb's Phase 2 RELATIVITY-104 trial showed improved responses in certain lung cancer patients when adding a second immunotherapy to existing checkpoint inhibitor and chemotherapy, leading to a Phase 3 study.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Roche's subcutaneous Tecentriq approved for cancer treatment; Gilead's twice-yearly HIV shot reduces infection risk by 96%; Biogen appoints Lloyd Minor and Menelas Pangalos as independent directors; Sanofi secures rights to a rare cancer radiopharmaceutical; Eli Lilly to expand Irish manufacturing for Alzheimer's drug Kisunla.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

John joins Trialbee for its global team, industry-leading patient recruitment platform, and Swedish culture, aiming to contribute to equity in clinical research.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.